ICH Q and A demystifies periodic benefit-risk evaluation reporting
This article was originally published in SRA
The International Conference on Harmonisation has issued a new Q&A document to clarify the guideline it finalized in November 2012 on periodic benefit-risk evaluation reporting (PBRER) on marketed medicines1,2.
You may also be interested in...
The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.